gets FDA nod for cardiomyopathy algorithm

2021 07 16 16 27 9194 Artificial Intelligence Ai Abstract 400

Artificial intelligence (AI) software developer has secured de novo approval by the U.S. Food and Drug Administration (FDA) for its cardiomyopathy AI detection algorithm.

Integrated into the Platform, the algorithm automatically reviews routine electrocardiograms, which can help with coordinating follow-up echocardiography exams for diagnosis and using the Viz Echo Viewer to review images and access echocardiogram reports, according to the vendor.

The company said the deployment of the algorithm is financially supported by a multiyear agreement with Bristol Myers Squibb, announced in March.

Page 1 of 573
Next Page